Ignite Creation Date:
2025-12-24 @ 11:42 PM
Ignite Modification Date:
2025-12-25 @ 9:34 PM
Study NCT ID:
NCT05672251
Status:
RECRUITING
Last Update Posted:
2025-10-06
First Post:
2023-01-03
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sponsor:
City of Hope Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-01-02
Start Date Type:
ACTUAL
Primary Completion Date:
2026-04-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-04-07
Completion Date Type:
ESTIMATED
First Submit Date:
2023-01-03
First Submit QC Date:
None
Study First Post Date:
2023-01-05
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-02
Last Update Post Date:
2025-10-06
Last Update Post Date Type:
ESTIMATED